ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue13,073.2596,473.978-
Cost of Revenue7,419.9884,853.664-
Gross Profit5,653.2711,620.314-
Operating Expenses
Research Development7,526.7849,697.1364,843.139
Selling General and Administrative22,819.22417,127.5559,007.289
Non Recurring96.34696.34696.346
Others---
Total Operating Expenses---
Operating Income or Loss-24,789.083-25,204.377-13,850.428
Income from Continuing Operations
Total Other Income/Expenses Net-857.9971,406.756278.431
Earnings Before Interest and Taxes-25,647.08-23,797.621-13,571.997
Interest Expense231.291214.396214.396
Income Before Tax-25,878.371-24,012.017-13,571.997
Income Tax Expense-339.391-4,574.765-
Minority Interest---
Net Income From Continuing Ops-25,538.98-19,437.252-13,571.997
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-25,538.98-19,437.252-13,571.997
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-25,538.98-20,811.481-13,571.997